Table 2.
Univariate analysis of prognostic factors for 272 patients with stage III NPC
| Variables | LRFS | DMFS | DFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Sex (male vs. female) | 0.978 (0.400–2.392) | 0.961 | 0.922 (0.462–1.840) | 0.818 | 0.874 (0.499–1.530) | 0.637 | 0.779 (0.407–1.491) | 0.451 |
| Age (≤ 43 vs. > 43, year) | 1.254 (0.612–2.570) | 0.537 | 1.224 (0.706–2.122) | 0.471 | 1.450 (0.936–2.247) | 0.096 | 2.087 (1.252–3.480) | 0.005 |
| Smoking (yes vs. no) | 0.662 (0.323–1.357) | 0.260 | 0.618 (0.356–1.073) | 0.087 | 0.617 (0.399–0.953) | 0.030 | 0.472 (0.286–0.781) | 0.003 |
| Alcohol (yes vs. no) | 0.749 (0.321–1.746) | 0.503 | 0.748 (0.392–1.430) | 0.380 | 0.707 (0.427–1.170) | 0.177 | 0.594 (0.341–1.035) | 0.066 |
| T classification (T1-2 vs. T3) | 1.486 (0.371–2.014) | 0.735 | 1.580 (0.445–1.623) | 0.622 | 1.268 (0.520–1.451) | 0.590 | 1.069 (0.581–1.966) | 0.830 |
| N classification (N0-1 vs. N2) | 1.890 (0.923–3.873) | 0.082 | 1.672 (0.965–2.895) | 0.067 | 1.670 (1.083–2.575) | 0.020 | 1.506 (0.922–2.459) | 0.102 |
| CCT (yes vs. no) | 1.721 (0.828–3.575) | 0.146 | 1.485 (0.842–2.620) | 0.172 | 1.721 (1.106–2.678) | 0.016 | 1.976 (1.205–3.239) | 0.007 |
| EBV DNA (< 2000 vs. ≥ 2000) | 1.747 (0.750–4.071) | 0.196 | 1.398 (0.756–2.585) | 0.286 | 1.084 (0.684–1.718) | 0.732 | 1.081 (0.649–1.802) | 0.764 |
NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; LRFS, locoregional-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival; CCT, concurrent chemotherapy; EBV, Epstein–Barr virus